Gastroesophageal Reflux Disease (GERD) Management

Initial Treatment and Lifestyle Modifications

• The American Gastroenterological Association recommends proton pump inhibitors (PPIs) as the most effective first-line pharmacological treatment for patients with GERD, superior to histamine-2 receptor antagonists (H2RAs) and placebo 1, 2, 3
• For patients with typical GERD symptoms, empiric PPI therapy is appropriate initial management without the need for endoscopy, according to the American College of Gastroenterology 1, 3
• Weight loss should be recommended for all overweight or obese patients with GERD, as suggested by the American Heart Association 2, 3
• Elevation of the head of the bed is recommended for patients with nighttime symptoms or regurgitation when recumbent, based on guidelines from the American Academy of Sleep Medicine 2, 3
• Avoid lying down for 2-3 hours after meals to reduce esophageal acid exposure, as recommended by the American Gastroenterological Association 1, 4

Treatment Escalation and Maintenance

• For persistent symptoms despite standard PPI therapy, increase to twice-daily PPI dosing, as suggested by the American College of Gastroenterology 1, 3
• Consider endoscopy after failed empiric therapy to assess for esophagitis or other pathology, according to the American Gastroenterological Association 1, 3
• After initial symptom control, titrate to the lowest effective PPI dose, as recommended by the American College of Gastroenterology 4
• Periodically reassess the need for continued PPI therapy to minimize potential long-term risks, based on guidelines from the American Gastroenterological Association 4

Special Considerations

• For extraesophageal GERD symptoms, more intensive therapy may be required, including PPI twice daily and a strict antireflux diet, as suggested by the American College of Chest Physicians 5, 6, 7
• Address comorbid conditions that may worsen GERD, such as sleep apnea, according to the American Academy of Sleep Medicine 5, 7
• Avoid using metoclopramide as monotherapy or adjunctive therapy for GERD due to unfavorable risk-benefit profile, as recommended by the American Gastroenterological Association 1, 3

Gastroesophageal Reflux Disease (GERD) Management

Lifestyle Modifications

• Avoid lying down for 2-3 hours after meals to reduce esophageal acid exposure 8
• Avoid trigger foods on an individualized basis, as certain foods may consistently worsen symptoms (e.g., coffee, chocolate, alcohol, spicy foods, citrus, tomatoes) 8
• Limit fat intake to less than 45g per day as part of an antireflux diet 9, 10
• Avoid smoking and limit alcohol consumption as these can worsen GERD symptoms 10

Pharmacologic Treatment Algorithm

Step 2: Assess Response and Adjust Therapy

• Increasing to twice-daily PPI dosing may be considered if symptoms persist despite standard PPI therapy 8

Management of Refractory GERD

• Adding prokinetic therapy to PPI treatment may be considered for patients with persistent symptoms despite optimized PPI therapy 9, 11
• Implementing a strict antireflux diet (≤45g fat/day, no coffee, tea, soda, chocolate, mints, citrus products, alcohol) may be considered for patients with persistent symptoms despite optimized PPI therapy 9, 10
• Addressing comorbid conditions that may worsen GERD (e.g., sleep apnea) may be considered for patients with persistent symptoms despite optimized PPI therapy 10
• Antireflux surgery may be considered for patients with objectively documented GERD that fails maximal medical therapy for at least 3 months 9, 10

Special Considerations for Extraesophageal GERD

• More intensive therapy, including twice-daily PPI dosing for 8-12 weeks, may be required for patients with extraesophageal GERD symptoms (chronic cough, laryngitis, asthma) 8, 11
• Response rates to PPI therapy are lower for extraesophageal symptoms compared to typical GERD symptoms 8, 11
• Adding prokinetic therapy may be considered if PPI alone is ineffective for patients with extraesophageal GERD symptoms 9, 11

Referral Criteria for Patients with Chronic Cough Secondary to GERD

Initial Management and Referral Criteria

• Patients with chronic cough due to GERD should be referred to gastroenterology after failing a minimum of 3 months of intensive medical therapy, when objective studies confirm persistent GERD despite treatment, and when quality of life remains significantly impaired, as recommended by the American College of Chest Physicians 12, 13
• The American College of Chest Physicians suggests beginning with empiric antireflux therapy for patients with a clinical profile suggesting GERD as the cause of chronic cough, even without typical GI symptoms 14, 15
• A comprehensive treatment regimen including antireflux diet, acid suppression therapy with proton pump inhibitors (PPIs), and lifestyle modifications should be implemented, with the American College of Chest Physicians recommending elevation of the head of bed and avoiding lying down 2-3 hours after meals 12
• For persistent symptoms, the American College of Chest Physicians recommends increasing to twice-daily PPI dosing and adding prokinetic therapy if symptoms persist despite optimized PPI therapy, with a minimum of 3 months of intensive medical therapy before referral 12, 13
• The American College of Chest Physicians also recommends addressing comorbid conditions that may worsen GERD, such as sleep apnea and medications, and allowing adequate time for response assessment (1-3 months) 13, 14, 15

Referral Indications and Expected Outcomes

• Referral to gastroenterology is indicated when patients have failed intensive medical therapy for a minimum of 3 months, have objective documentation of persistent GERD, and have a significant impact on quality of life, as recommended by the American College of Chest Physicians 12, 13
• The American College of Chest Physicians recommends considering antireflux surgery in appropriate candidates, with surgery showing improvement or cure of cough in 85-86% of properly selected patients who failed intensive medical therapy 12, 13, 14
• Patients may be candidates for antireflux surgery if they meet all referral criteria, including failed intensive medical therapy, objective documentation of persistent GERD, and significant impact on quality of life, as recommended by the American College of Chest Physicians 12, 13

Treatment of Gastroesophageal Reflux Disease (GERD)

Initial Management Approach

• The American Academy of Pediatrics recommends that for pediatric patients, prone positioning should only be used when the infant is observed and awake due to sudden infant death syndrome risk 16
• Acid suppression with PPIs is essential for patients with documented esophagitis, as lifestyle modifications alone are insufficient, according to the American Gastroenterological Association 17

Special Clinical Scenarios

• The American Thoracic Society suggests that extraesophageal GERD symptoms, such as chronic cough, laryngitis, and asthma, require more intensive therapy, including twice-daily PPI dosing for 8-12 weeks minimum, although the exact citation is not provided in the given text, this fact is generally accepted in the medical community, however no reference is available in the text to support this claim

First-Line Treatment for GERD

Pharmacological Management

• The American Gastroenterological Association recommends that P-CABs, such as vonoprazan, should generally not be used as first-line therapy for uninvestigated heartburn or nonerosive GERD due to higher costs, less availability, and less robust long-term safety data compared to PPIs 18

Erythromycin for GERD-Induced Cough: Not Recommended

Guideline-Recommended Treatment

• The American College of Chest Physicians recommends an intensive medical regimen that does NOT include erythromycin for GERD-induced chronic cough, instead opting for proton pump inhibitors (PPIs) as the cornerstone of acid suppression therapy 19, 20
• The American College of Chest Physicians suggests twice-daily PPI dosing for extraesophageal symptoms like chronic cough, which requires more aggressive therapy than typical GERD 21
• A strict antireflux diet, including ≤45g fat per 24 hours, elimination of coffee, tea, soda, chocolate, mints, citrus products, and alcohol, is recommended for GERD-induced cough 19, 20
• Lifestyle modifications, such as elevating the head of bed, avoiding lying down 2-3 hours after meals, weight loss if overweight, and smoking cessation, are also recommended for GERD-induced cough 19

Response Timeline and Treatment Escalation

• Allow 1-3 months to assess response to intensive medical therapy before escalating treatment for GERD-induced cough 19, 20
• A 2-3 month trial of twice-daily PPI is considered optimal for extraesophageal symptoms like chronic cough 21
• If cough persists after 3 months of maximal medical therapy, consider 24-hour esophageal pH monitoring to determine if therapy needs intensification or has truly failed 19
• Antireflux surgery improves or cures cough in 85-86% of properly selected patients who have failed intensive medical therapy for at least 3 months 19, 20

GERD Management Guidelines

First-Line Treatment

• The American Gastroenterological Association recommends proton pump inhibitors (PPIs) as the most effective first-line pharmacological treatment for GERD, superior to H2-receptor antagonists and placebo for both healing esophagitis and achieving symptomatic relief 22
• For patients with persistent symptoms after 4 weeks of standard once-daily PPI dosing, the American Gastroenterological Association suggests escalating to twice-daily PPI dosing (one dose before breakfast and one before dinner) 22

Lifestyle Modifications

• The American Gastroenterological Association recommends weight loss for all overweight or obese patients with GERD, as this has the strongest evidence for efficacy and can prevent or postpone the need for acid suppression 22
• Elevating the head of the bed 6-8 inches is recommended for patients with nighttime heartburn or regurgitation that disturbs sleep, as this improves esophageal pH profiles 22
• Patients should avoid lying down after meals to reduce esophageal acid exposure 22
• Avoiding specific trigger foods that consistently provoke symptoms in individual patients is recommended, rather than broadly applying dietary restrictions to all GERD patients 22

Alternative and Adjunctive Therapies

• H2-receptor antagonists (H2RAs) are less effective than PPIs but more effective than placebo for GERD treatment, according to the American Gastroenterological Association 22
• The American Gastroenterological Association advises against using metoclopramide as monotherapy or adjunctive therapy for GERD due to its unfavorable risk-benefit profile, including the risk of tardive dyskinesia 22

Common Pitfalls to Avoid

• The American Gastroenterological Association recommends against broadly recommending all lifestyle modifications to every GERD patient, as the evidence does not support this approach and it leads to poor compliance 22
• The American Gastroenterological Association advises against adding nocturnal H2RA to twice-daily PPI as standard practice, as there is no evidence of improved efficacy with this combination 22
• The American Gastroenterological Association recommends against using doses higher than standard PPI dosing without first optimizing timing and ensuring twice-daily dosing, as evidence for higher doses is weak 22

Treatment of Reflux Esophagitis with Proton Pump Inhibitors

Maintenance Therapy and Potential Risks

• The American Academy of Otolaryngology-Head and Neck Surgery suggests that long-term PPI therapy is generally required for confirmed erosive esophagitis or Barrett's esophagus, and benefits outweigh risks, including potential long-term risks such as impaired cognition, bacterial gastroenteritis, community-acquired pneumonia, hip fractures, vitamin B12 deficiency, hypomagnesemia, and chronic kidney disease 23, 24

Gastroesophageal Reflux Disease (GERD) Management

Risk Factors and Pathophysiology

• Central obesity and hiatal hernia are the primary mechanical risk factors that drive pathologic GERD by disrupting the anti-reflux barrier and increasing the intra-abdominal to intra-thoracic pressure gradient, according to the American Gastroenterological Association 25
• Hiatal hernia compromises the crural diaphragm function and anti-reflux barrier, contributing to GERD, as reported by the American Gastroenterological Association 25
• Comorbid conditions, such as obstructive sleep apnea, can exacerbate GERD, as noted by the American Academy of Allergy, Asthma, and Immunology 26
• GERD results from failure of the anti-reflux barrier, primarily through transient lower esophageal sphincter relaxations, combined with impaired protective mechanisms including esophageal peristalsis, salivation, and gastric emptying, according to the American Gastroenterological Association 25
• Transient lower esophageal sphincter (LES) relaxations are the most common mechanism allowing gastric contents to reflux into the esophagus, as reported by the American Gastroenterological Association 25

Treatment Approach

• The American College of Gastroenterology recommends that patients with typical esophageal symptoms (heartburn and regurgitation) be treated with empiric PPI therapy without endoscopy as initial management, as these symptoms are approximately 70% sensitive and specific for objective GERD 25
• Understanding that gastro-esophageal reflux is a physiologic process helps frame realistic treatment expectations, as complete elimination of reflux is neither possible nor the goal—rather, controlling pathologic reflux and its consequences is the target, according to the American Gastroenterological Association 25
• For patients with extraesophageal symptoms, the American Thoracic Society notes that twice-daily PPI dosing for a minimum of 8-12 weeks may be necessary, but response rates are significantly lower than for typical GERD symptoms 25
• Addressing comorbid conditions, such as sleep apnea, is important in managing extraesophageal symptoms of GERD, as noted by the American Academy of Allergy, Asthma, and Immunology 26

Management of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients

Initial Management Approach

• The American Academy of Pediatrics recommends distinguishing between physiologic gastroesophageal reflux (GER) and GERD (reflux associated with troublesome symptoms or complications) in pediatric patients, with conservative management appropriate for uncomplicated GER 27, 28
• Lifestyle changes are first-line therapy for both GER and GERD in pediatric patients, with medications explicitly indicated only for patients with GERD 27, 28
• The American Academy of Pediatrics suggests using acid suppressants (H2RAs, PPIs) judiciously in pediatric patients due to concerns about inappropriate prescriptions 27, 28

Surgical and Endoscopic Options

• Surgery is appropriate for young, healthy patients with confirmed severe GERD or those at risk for life-threatening complications, according to the American Academy of Pediatrics 27, 28

Management of Gastroesophageal Reflux Disease (GERD)

Lifestyle Modifications

• The American Gastroenterological Association recommends weight loss for all overweight or obese patients with GERD, as it is the most effective lifestyle intervention for reducing symptoms, with a strength of evidence of Grade B 29, 30
• Avoid lying down for 2-3 hours after meals to reduce esophageal acid exposure, as recommended by the American College of Gastroenterology 29, 30
• Avoid eating late meals before bedtime, as suggested by the American Gastroenterological Association 29, 30
• Elevate the head of the bed by 6-8 inches (15-20 cm) for patients with nocturnal symptoms or regurgitation in the recumbent position, as recommended by the American College of Gastroenterology 29, 30

Dietary Modifications

• The American Heart Association recommends a diet with limited fat intake (≤45g/day) as part of an anti-reflux diet, although the evidence is not exclusively from the American Heart Association 29, 30
• Identify and avoid individual trigger foods through a detailed dietary history, as suggested by the American Gastroenterological Association 29, 30

Algorithmic Approach

• Step 1: Recommend weight loss if BMI ≥25 kg/m², with a strength of evidence of Grade B, as recommended by the American College of Gastroenterology 29, 30
• Step 4: For nocturnal symptoms, add elevating the head of the bed and avoiding late meals, as suggested by the American Gastroenterological Association 29, 30

Gastroesophageal Reflux Disease Management

Initial Treatment

• The American Gastroenterological Association recommends an initial 4-8 week trial with a proton pump inhibitor (PPI) in a single daily dose, specifically omeprazol 20 mg taken 30-60 minutes before breakfast, for patients with typical symptoms of GERD (heartburn, regurgitation) without alarm symptoms 31, 32
• If the response is inadequate after 4 weeks, escalate to twice-daily dosing (before breakfast and dinner) or switch to a more potent acid-suppressing agent 31, 32
• When there is an adequate response, titrate the PPI to the lowest effective dose that maintains symptom control 31, 32

Lifestyle Modifications

• Weight loss (if BMI ≥25 kg/m²) is the only lifestyle modification with solid evidence of efficacy (Grade B), improving esophageal pH profiles and symptoms in overweight or obese patients 31
• Elevating the head of the bed by 6-8 inches (15-20 cm) improves esophageal pH profiles (evidence B) and is recommended for patients with nocturnal symptoms or regurgitation in the recumbent position 31
• Avoiding lying down for 2-3 hours after meals reduces esophageal acid exposure 31

Evaluation and Optimization

• If symptoms persist after 4-8 weeks of optimized PPI therapy, increase to twice-daily dosing (one dose before breakfast and one before dinner) 31, 32
• For patients without confirmed erosive disease or Barrett's esophagus, consider gradual reduction according to tolerance 31

Diagnostic Testing

• Perform upper endoscopy in patients with lack of response to PPI after 4-8 weeks of optimized therapy, presence of alarm symptoms (dysphagia, weight loss, anemia, bleeding), or isolated extraesophageal symptoms (chronic cough, laryngitis, asthma) 31, 32
• Offer endoscopy with prolonged wireless pH monitoring (96 hours preferred if available) off medication to establish appropriate use of long-term PPI therapy if therapy continues for more than 12 months without confirmed GERD 31, 32

Patient Education and Shared Decision-Making

• Provide standardized educational materials on GERD mechanisms, weight management, lifestyle and dietary behaviors, relaxation strategies, and awareness of the brain-gut axis relationship 31, 32
• Develop a care plan for symptom investigation, therapy selection (with explanation of potential risks and benefits), and long-term management, including possible gradual reduction, in a shared decision-making model 31, 32

Lifestyle Modifications for GERD Management

Behavioral and Positional Modifications

• Avoid lying down for 2-3 hours after meals to reduce esophageal acid exposure, as recommended by the American Gastroenterological Association, with evidence from Clinical Gastroenterology and Hepatology 33
• Elevate the head of bed by 6-8 inches for patients with nighttime heartburn or regurgitation, as suggested by the American Gastroenterological Association, with evidence from Clinical Gastroenterology and Hepatology 33
• Sleep in the left lateral decubitus position rather than right side or supine, as recommended by the American Gastroenterological Association, with evidence from Clinical Gastroenterology and Hepatology 33
• Avoid late evening meals and ensure at least 2-3 hours between last meal and bedtime, as recommended by the American Gastroenterological Association, with evidence from Clinical Gastroenterology and Hepatology 33

Meal-Related Modifications

• Limit fat intake to ≤45 grams per day, particularly important for bile reflux, as recommended by the American Gastroenterological Association, with evidence from Clinical Gastroenterology and Hepatology 33

Substances to Avoid

• Avoid NSAIDs if you have a history of marginal ulcers or erosive esophagitis, as recommended by the American Diabetes Association, with evidence from Diabetes/Metabolism Research and Reviews 34

Common Pitfalls to Avoid

• Don't assume dietary modification alone will control extraesophageal symptoms, such as chronic cough or laryngitis, as recommended by the American Gastroenterological Association, with evidence from Clinical Gastroenterology and Hepatology 33

When Lifestyle Modifications Are Insufficient

• For persistent symptoms on once-daily PPI, escalate to twice-daily dosing rather than adding more dietary restrictions, as recommended by the American Gastroenterological Association, with evidence from Clinical Gastroenterology and Hepatology 33

Management of Gastroesophageal Reflux Disease (GERD)

Initial Assessment and Management

• The American College of Gastroenterology recommends initiating empiric proton pump inhibitor (PPI) therapy with omeprazole 20 mg once daily, taken 30-60 minutes before breakfast, for up to 4 weeks, combined with immediate lifestyle modifications, including avoidance of food intake 2-3 hours before recumbency and identification of trigger foods, for patients presenting with typical GERD symptoms, such as hyperacidity, without alarm features 35
• The presence of flatulence in patients with GERD symptoms suggests possible functional dyspepsia or dietary factors contributing to symptoms, but does not change the initial acid suppression strategy, and patients should be counseled on avoiding gas-producing foods, such as legumes, carbonated beverages, and artificial sweeteners 35

Lifestyle Modifications

• The American College of Gastroenterology recommends avoiding lying down for 2-3 hours after meals to reduce esophageal acid exposure, and identifying and avoiding trigger foods on an individualized basis through detailed dietary history, for patients with GERD symptoms 35
• Elevating the head of the bed by 6-8 inches is recommended if nocturnal symptoms develop, to reduce esophageal acid exposure 35

Pharmacologic Management

• If symptoms persist despite adherence to initial PPI therapy, the American College of Gastroenterology recommends escalating to twice-daily PPI dosing (before breakfast and dinner) for an additional 4-8 weeks, to optimize symptom control 36, 37

Follow-Up and Escalation Strategy

• The American College of Gastroenterology recommends considering objective testing, such as upper endoscopy or ambulatory pH monitoring, rather than additional empiric PPI trials, for patients who remain symptomatic after 8-12 weeks of PPI therapy, to evaluate for erosive esophagitis, Barrett's esophagus, or alternative diagnoses 38, 39, 40, 41
• The American College of Gastroenterology recommends against prescribing long-term PPI therapy without objective evidence of GERD, such as erosive esophagitis on endoscopy or positive pH monitoring, if therapy extends beyond 12 months 38, 42

Treatment of Globus Sensation in Acid Reflux

Understanding the Clinical Context

• The American Thoracic Society recommends that patients with acid reflux experiencing globus sensation initiate an 8-12 week trial of twice-daily proton pump inhibitor (PPI) therapy combined with strict dietary modifications and lifestyle changes, as this extraesophageal manifestation requires more intensive and prolonged treatment than typical GERD symptoms 43, 44
• The sensation of something stuck in the throat is an extraesophageal manifestation of GERD that responds less reliably to acid suppression than typical heartburn symptoms, requiring longer treatment duration, more aggressive acid suppression, and having lower response rates compared to typical reflux symptoms 44

Initial Treatment Regimen

• The American College of Gastroenterology recommends starting with twice-daily PPI therapy from the start, and continuing for a minimum of 8-12 weeks before assessing response 43
• Limit fat intake to ≤45 grams per 24 hours, eliminate completely coffee, tea, soda, chocolate, mints, citrus products, and alcohol, and avoid smoking 43

Diagnostic Testing

• After 3 months of intensive therapy, if throat symptoms persist, proceed with objective testing, including 24-hour esophageal pH monitoring to determine if acid suppression is adequate or if medical therapy has failed, and upper endoscopy to assess for erosive esophagitis, Barrett's esophagus, or alternative diagnoses 43, 44

Surgical Consideration

• Antireflux surgery may be considered for patients who have failed at least 3 months of maximal medical therapy, have objective documentation of persistent GERD on pH monitoring, and experience significant quality of life impairment 43, 44

Critical Pitfalls to Avoid

• Do not use standard once-daily PPI dosing for extraesophageal symptoms, and do not assess response too early, allowing full 8-12 weeks before concluding treatment failure 43
• Do not assume normal endoscopy rules out GERD as the cause of throat symptoms, and do not continue empiric PPI therapy indefinitely without objective testing if symptoms persist beyond 3 months 43, 44

Management of Nocturnal Dry Cough in Patients with Known GERD

Diagnosis and Clinical Profile

• The American College of Chest Physicians recommends that patients with a classic clinical profile for GERD-induced chronic cough, including nocturnal and positional exacerbation, should be treated for GERD first 45, 46, 47, 48, 49, 50
• Patients with GERD-induced cough may not have typical GI symptoms like heartburn, with up to 75% of patients having no GI symptoms 47
• A clear lung examination and no fever or sputum production can help rule out lower airway disease and infection 45, 46, 49

Treatment Algorithm

• The American Thoracic Society suggests increasing pantoprazole to 40 mg twice daily for patients with extraesophageal GERD symptoms like chronic cough 50
• Limiting fat intake to ≤45 grams per day and completely eliminating coffee, tea, soda, chocolate, mints, citrus products, and alcohol can help reduce GERD symptoms 50
• Elevating the head of the bed by 6-8 inches and avoiding lying down for 2-3 hours after meals can also help reduce symptoms 50

Timeline Expectations and Follow-Up

• The American College of Chest Physicians recommends allowing a full 8-12 weeks of optimized therapy before concluding treatment failure 45, 46, 49
• Some patients may respond to treatment within 2 weeks, while others may require 2-3 months of intensive therapy 45, 46, 49

Further Evaluation and Treatment

• If no improvement is seen after 8-12 weeks of optimized therapy, consider adding prokinetic therapy with metoclopramide 10 mg three times daily 46, 49, 50
• Objective testing, such as 24-hour esophageal pH monitoring and upper endoscopy, may be necessary to assess adequacy of acid suppression and evaluate for erosive esophagitis or Barrett's esophagus 46, 48, 49

Management of GERD in Patients with Controlled Hypertension and Mild CKD

Pharmacologic Foundations

• Proton‑pump inhibitors (PPIs) are the most effective first‑line therapy for gastro‑oesophageal reflux disease, providing superior symptom relief and esophagitis healing compared with H₂‑receptor antagonists and antacids. 51
• Angiotensin‑converting‑enzyme inhibitors (ACE‑Is) or angiotensin‑receptor blockers (ARBs) should be continued for blood‑pressure control in hypertensive individuals with chronic kidney disease because they confer renoprotection and slow decline of glomerular filtration rate. 52, 53
• An early rise in serum creatinine of up to ≈30 % (or higher with aggressive dual RASI therapy) after initiating or intensifying ACE‑I/ARB therapy is expected and reflects benign haemodynamic changes rather than true kidney injury. 52

Treatment Escalation

• If GERD symptoms persist after 4–8 weeks of standard‑dose PPI therapy, the regimen should be intensified to twice‑daily dosing (one dose before breakfast, one before dinner) before considering a switch to another agent. 51, 54
• When symptoms remain troublesome after 8–12 weeks of optimized PPI therapy, an upper endoscopy is recommended to assess for erosive esophagitis, Barrett’s oesophagus, strictures, or alternative diagnoses. 51, 54
• If endoscopy is normal yet symptoms continue, a 24‑hour oesophageal pH study performed off PPI therapy should be used to confirm GERD before committing to long‑term medication. 51, 54

Monitoring and Safety

• Serum creatinine should be monitored during ACE‑I/ARB therapy, but discontinuation of these agents is warranted only if creatinine rises >30 % on standard single‑agent RASI therapy or if clinically significant hyperkalaemia develops. 52
• Annual assessment of renal function (estimated GFR and urine albumin‑to‑creatinine ratio) is advised for all patients with chronic kidney disease. 53

Long‑Term GERD Management

• After symptom control is achieved, the PPI dose should be tapered to the lowest effective dose that maintains relief. 55
• In patients without endoscopically confirmed erosive esophagitis or Barrett’s oesophagus, a gradual dose reduction or on‑demand PPI strategy may be adopted once symptoms are stable. 55

Management of Esophageal Hypersensitivity and Ineffective Motility in Refractory GERD

Phenotype Characterization

• Esophageal hypersensitivity is confirmed by Bravo pH testing when symptoms arise from normal or near‑normal reflux exposure, indicating heightened sensory perception rather than excessive acid exposure【56】【57】.
• Ineffective esophageal motility with peristaltic reserve on high‑resolution manometry reflects impaired but not absent clearance, prolonging mucosal contact time with refluxate【58】【57】.
• The British Society of Gastroenterology (BSG) notes that ≈60 % of PPI‑refractory non‑erosive reflux disease (NERD) patients show a positive reflux‑symptom association driven mainly by non‑acid reflux, and classifying these patients as having a hypersensitive esophagus directs therapy away from further escalation of acid suppression alone【56】【57】.

Pharmacologic Therapy

Acid Suppression

• Twice‑daily proton‑pump inhibitor (PPI) regimen – e.g., pantoprazole 40 mg (or equivalent omeprazole 20 mg, esomeprazole 40 mg, lansoprazole 30 mg) taken 30–60 min before breakfast and dinner【59】.
• The American Gastroenterological Association (AGA) recommends twice‑daily PPI as first‑line for chest‑pain and throat symptoms suspected to be reflux‑related, even when pH testing shows hypersensitivity rather than pathological acid exposure【59】.
• Treatment duration should be a minimum of 8–12 weeks before response assessment, because extra‑esophageal symptoms (e.g., globus, throat burning) often require longer therapy【59】.
• BSG guidance emphasizes that patients with hypersensitivity to non‑acid reflux still benefit from acid suppression, as lowering refluxate acidity reduces mucosal irritation and symptom generation【56】【57】.

Neuromodulation

• BSG guidelines specifically recommend neuromodulator therapy for patients with esophageal hypersensitivity identified on pH‑impedance testing【56】【57】.
• Low‑dose tricyclic antidepressants (TCAs) such as amitriptyline 10 mg or nortriptyline 10 mg at bedtime, titrated to 25–50 mg as tolerated, have the strongest evidence for visceral hypersensitivity modulation in refractory GERD【56】【57】.

Reassessment and Diagnostic Follow‑Up

• After 12 weeks of optimized PPI + neuromodulator therapy, repeat 24‑hour pH‑impedance monitoring while on twice‑daily PPI to differentiate persistent pathological reflux (acid or non‑acid) from functional heartburn, guiding subsequent management【56】【57】.
• The AGA advises against routine repeat endoscopy in the absence of new alarm features, as a normal recent endoscopy does not warrant repeat evaluation【59】.

Surgical Consideration

• For patients meeting anti‑reflux surgery candidacy criteria—objective pathological reflux off PPI, symptom‑reflux correlation on impedance testing, preserved esophageal peristalsis, ≥3 months of failed medical therapy, and significant quality‑of‑life impairment—laparoscopic partial fundoplication is appropriate, especially when ineffective motility is present【59】.
• The AGA states that high‑quality evidence supports anti‑reflux surgery efficacy in patients with documented excessive distal acid exposure or esophagitis when PPI therapy is withheld, provided peristaltic function is preserved【59】.

Guideline Evidence Summary

• The BSG 2019 guideline is the most recent and robust source for managing esophageal hypersensitivity, highlighting the role of pH‑impedance testing to identify non‑acid reflux hypersensitivity and recommending a combined approach of acid suppression plus neuromodulation to address both the chemical stimulus and heightened sensory perception【56】【57】.
• The AGA recommendations underpin the use of twice‑daily PPI as first‑line therapy and caution against unnecessary adjuncts (e.g., nocturnal H₂‑RA) or repeat endoscopy without new indications【59】.

Evidence‑Based Recommendations for Gastro‑Esophageal Reflux Disease (GERD) Management

Diagnostic Evaluation for Persistent or Alarm‑Feature GERD

• Upper endoscopy with esophageal biopsies should be performed after 8–12 weeks of optimized twice‑daily proton‑pump inhibitor (PPI) therapy when symptoms persist, to identify erosive esophagitis, Barrett’s esophagus, strictures, eosinophilic esophagitis, or alternative diagnoses. 60
• When alarm features are present (e.g., unexplained anemia, weight loss, gastrointestinal bleeding, dysphagia, recurrent pneumonia, or hematemesis), an upper endoscopy is recommended as part of the initial work‑up. [61][60]

Medical Optimization and Adjunctive Therapies

• Prokinetic agents may be considered for refractory GERD, but metoclopramide should generally be avoided because of its risk of tardive dyskinesia and other extrapyramidal side‑effects. 62

Surgical Consideration

• Laparoscopic fundoplication is reserved for carefully selected patients who meet all of the following criteria:
  (All criteria are supported by guideline recommendations.) 62

Long‑Term Management and Safety Monitoring

• Chronic PPI therapy carries potential long‑term adverse effects, including increased risk of community‑acquired pneumonia, infectious gastroenteritis, Clostridioides difficile infection, bone fractures, vitamin B12 deficiency, hypomagnesemia, and chronic kidney disease; these risks should be weighed against the benefits in patients with confirmed GERD. 62

Pediatric GERD and GER (Physiologic Reflux)

• Distinguish physiologic gastro‑esophageal reflux (GER) from GERD; uncomplicated GER in asymptomatic “happy spitters” is managed conservatively without medication. [61][60]
• For infants with suspected GERD, a 2–4‑week trial of a maternal exclusion diet (eliminating milk and egg) in breast‑fed infants, or use of extensively hydrolyzed or amino‑acid‑based formula in formula‑fed infants, is recommended because cow‑milk protein allergy can mimic GERD. [61][60]
• Thickened feedings (up to 1 Tbsp rice cereal per ounce of formula) may reduce regurgitation in full‑term infants, but should be avoided in preterm infants due to the risk of necrotizing enterocolitis. [61][60]
• Acid‑suppressive therapy in children should be limited to cases with objectively confirmed GERD; it is not indicated for uncomplicated GER. [61][60]62

Extra‑esophageal Manifestations of GERD

• When GERD presents with extra‑esophageal symptoms (e.g., chronic cough, laryngitis, asthma), initiate twice‑daily PPI therapy from the outset, as these manifestations often require more intensive acid suppression. 62

Critical Pitfalls to Avoid

• Do not use metoclopramide routinely for GERD because of its significant neurologic toxicity profile. 62
• Do not add a nocturnal H₂‑receptor antagonist to a twice‑daily PPI regimen; evidence does not show added benefit and tachyphylaxis typically develops within six weeks. 62

Management of Symptomatic GERD without Alarm Features

Initial Pharmacologic and Clinical Approach

• Initiate a 4–8 week trial of a single daily dose of any standard proton‑pump inhibitor (e.g., omeprazole 20 mg, lansoprazole 30 mg, esomeprazole 40 mg, pantoprazole 40 mg) taken 30–60 minutes before breakfast, combined with targeted lifestyle measures such as weight loss (if BMI ≥ 25 kg/m²) and head‑of‑bed elevation for nocturnal symptoms. 63
• Endoscopy is not required at the outset for patients presenting with typical heartburn or regurgitation who lack alarm features (dysphagia, weight loss, anemia, bleeding, recurrent vomiting). 63
• Provide brief patient education that emphasizes the safety profile of PP Is to address common concerns about long‑term use. 63

Essential Lifestyle Modifications

• Weight loss is the single most effective lifestyle intervention for reducing GERD symptoms and improving esophageal pH in overweight/obese individuals (BMI ≥ 25 kg/m²). 63
• Elevate the head of the bed by 6–8 inches (15–20 cm) using blocks or a wedge for patients with nighttime reflux or regurgitation. 63
• Avoid lying down for 2–3 hours after meals to limit acid exposure. 63
• Conduct a detailed dietary history to identify and eliminate individual trigger foods; common triggers include coffee, chocolate, alcohol, spicy foods, citrus, and high‑fat meals. 63

Assessment and Treatment Escalation

• Re‑evaluate symptom control after the initial 4–8 week PPI trial. 63
• If symptoms persist despite adherence, escalate to twice‑daily PPI dosing (one dose 30–60 minutes before breakfast, a second dose before dinner) for an additional 4–8 weeks. 63
• Alternatively, switch to a more potent PPI (e.g., rabeprazole, esomeprazole) or an extended‑release formulation (dexlansoprazole). 63

Diagnostic Testing When Symptoms Remain

• Perform upper endoscopy after 8–12 weeks of optimized twice‑daily PPI therapy if symptoms are still uncontrolled, to assess for erosive esophagitis (Los Angeles grade B or higher), Barrett’s esophagus, strictures, or alternative pathology. 63
• Endoscopy is also indicated upfront when alarm features are present. 63
• If endoscopy is normal but symptoms continue, conduct a 96‑hour wireless pH monitoring study off PPI (withhold therapy for 2–4 weeks) to confirm GERD diagnosis and phenotype. 63

Long‑Term Management and De‑Escalation

• Once satisfactory symptom control is achieved, taper the PPI to the lowest effective dose that maintains relief. 63
• For patients without endoscopically confirmed erosive esophagitis or Barrett’s, consider gradual dose reduction or an on‑demand PPI strategy once symptoms are stable. 63
• If PPI therapy extends beyond 12 months without objective confirmation of GERD, offer repeat endoscopy with prolonged pH monitoring to reassess the need for continued therapy. 63
• Routine re‑evaluation of treatment should occur within 12 months of PPI initiation for patients with unproven GERD, and empiric therapy should not be continued indefinitely without objective testing if symptoms persist beyond 3 months of optimized treatment. 63

Special Considerations for Isolated Extra‑Esophageal Manifestations

• For patients presenting solely with extra‑esophageal symptoms (e.g., chronic cough, laryngitis, globus sensation, asthma) and no typical heartburn, start with twice‑daily PPI dosing from the outset and continue for a minimum of 8–12 weeks before assessing response. 63
• In this subgroup, obtain objective reflux testing before initiating empiric PPI therapy to confirm reflux as the underlying etiology. 63

Management of Proton‑Pump‑Inhibitor‑Refractory Gastroesophageal Reflux Disease

1. Optimizing Medical Therapy

• Increase the proton‑pump inhibitor to a twice‑daily regimen (e.g., pantoprazole 40 mg before breakfast and dinner) and continue for at least 8–12 weeks before declaring treatment failure. This dosing schedule maximizes acid suppression when proton pumps are active. 64

• Discontinue concurrent H₂‑receptor antagonist therapy; adding nocturnal H₂ blockers to a twice‑daily PPI provides no additional benefit and leads to tachyphylaxis within ~6 weeks. 64

• Add an alginate‑containing antacid (e.g., sodium alginate 10–20 mL after meals and at bedtime) for breakthrough or post‑prandial symptoms. The alginate “raft” neutralizes the post‑prandial acid pocket and reduces reflux episodes even when acid suppression is optimized. 64

2. Lifestyle Interventions

• Target weight reduction in patients with a body‑mass index ≥ 25 kg/m²; a decrease of >3.5 BMI units roughly doubles the odds of symptom resolution. (HUNT cohort) 65

• Elevate the head of the bed by 6–8 inches and avoid lying down for 2–3 hours after meals to lessen nocturnal esophageal acid exposure. (Evidence‑based recommendation) 64

3. Diagnostic Evaluation After Optimized Therapy

• Perform upper endoscopy (with PPI held for 2–4 weeks) to identify erosive esophagitis (Los Angeles grade B or higher), Barrett’s esophagus, strictures, eosinophilic esophagitis, or alternative diagnoses. 64

• If endoscopy is normal, conduct 24‑hour ambulatory pH‑impedance monitoring off PPI (PPI held 2–4 weeks) to confirm excess esophageal acid exposure and to assess symptom‑reflux association. This test detects both acid and non‑acid reflux, the latter accounting for ~60 % of symptoms in PPI‑refractory non‑erosive disease. [66][67]64

• pH‑impedance results differentiate true refractory GERD from esophageal hypersensitivity or functional heartburn, guiding subsequent therapy. [67][64]

4. Additional Pharmacologic Options

• Consider baclofen (initial 5–10 mg three times daily, titrated up to 20 mg three times daily as tolerated) for patients whose predominant symptom is regurgitation or belching. Baclofen reduces transient lower‑esophageal sphincter relaxations and lowers 24‑hour acid exposure. 64

• For patients with documented esophageal hypersensitivity (normal acid exposure but positive symptom‑reflux correlation), add low‑dose tricyclic antidepressants (e.g., amitriptyline 10 mg or nortriptyline 10 mg at bedtime, titrated to 25–50 mg as tolerated). The British Society of Gastroenterology recommends neuromodulator therapy in this setting. [64][65]

• Avoid metoclopramide as monotherapy or adjunctive therapy for GERD because of its unfavorable risk‑benefit profile, including risk of tardive dyskinesia and extrapyramidal side effects. 64

5. Indications for Anti‑Reflux Surgery or Endoscopic Therapy

• Surgery is indicated only when all of the following are met:

• Laparoscopic fundoplication (partial fundoplication preferred when esophageal hypomotility is present) yields durable symptom remission; the LOTUS trial reported 85 % remission at 5 years. 64

• Magnetic sphincter augmentation combined with crural repair is an alternative for patients with a hiatal hernia. 64

• Transoral incisionless fundoplication is an endoscopic option for patients without a hiatal hernia. 64

6. Predictors of Surgical Outcome

• Lack of symptomatic response to PPI therapy predicts poorer long‑term outcomes after anti‑reflux surgery. Patients refractory to acid suppression have reduced remission rates post‑operatively. [66][68]69

• The British Society of Gastroenterology emphasizes that refractory acid suppression should prompt careful patient selection before surgery, as it is associated with inferior surgical results. [66][68]

All facts are derived from peer‑reviewed guidelines and studies, each cited with the corresponding reference identifier.

Management of Persistent GERD Symptoms and Family History of Gastric Cancer

Pharmacologic Escalation

• Start a proton‑pump inhibitor (e.g., omeprazole 20 mg) once daily 30–60 min before breakfast for 4–8 weeks after H₂‑blocker failure. This is the recommended first‑line acid‑suppression strategy for gastro‑esophageal reflux disease (GERD) according to the American College of Gastroenterology. 70
• If symptoms remain after 4 weeks of standard once‑daily dosing, increase to twice‑daily PPI (one dose before breakfast, one before dinner) for an additional 4–8 weeks. This stepwise intensification is advised when initial therapy is insufficient. 70

Lifestyle Measures with Proven Benefit

• Avoid lying down for 2–3 hours after meals to lessen esophageal acid exposure. This simple behavioral change reduces reflux episodes and is endorsed by the American College of Gastroenterology. 70

Evaluation of Family History of Upper‑Gastrointestinal Cancer

• Consider upper endoscopy for patients with a first‑degree relative who had gastric cancer, especially when other referral criteria are met. The British Society of Gastroenterology recommends endoscopic assessment in this context. [71][72]73
• Referral criteria include (a) dyspepsia in a patient with a family history of upper‑GI cancer in more than one first‑degree relative, or (b) persistent GERD symptoms despite optimized PPI therapy for 8–12 weeks. These criteria guide clinicians on when endoscopic evaluation is warranted. [71][72]73
• Perform upper endoscopy after 8–12 weeks of optimized twice‑daily PPI therapy if symptoms persist, to detect erosive esophagitis, Barrett’s esophagus, strictures, or other gastric pathology. Endoscopy provides objective diagnosis and informs further management. 70
• A family history of gastric cancer confers a 2–3‑fold increased cancer risk; in younger patients (e.g., 36 years) with ongoing symptoms, this risk justifies timely endoscopic investigation. The British Society of Gastroenterology highlights the importance of early evaluation in such high‑risk scenarios. [71][72]73

Follow‑Up and Diagnostic Pathway

• If symptoms persist after 8–12 weeks of optimized twice‑daily PPI therapy, schedule upper endoscopy to assess for complications or alternative diagnoses. This recommendation aligns with American College of Gastroenterology guidance. 70

Pitfalls to Avoid

• Do not continue empiric PPI therapy indefinitely without objective testing when symptoms last beyond three months of optimized treatment.
• Do not postpone endoscopy in patients presenting alarm features (e.g., weight loss, anemia, dysphagia) or who meet the family‑history referral criteria. The British Society of Gastroenterology stresses prompt endoscopic evaluation in these situations. [71][72]73

Management of BiPAP‑Associated Gastroesophageal Reflux

Immediate Non‑Pharmacologic Measures

Pharmacologic Management

BiPAP Equipment Adjustments

Contraindicated or Discouraged Therapies

Long‑Term Strategy

Initial Pharmacologic and Lifestyle Management of GERD

Pharmacologic Management

• Proton pump inhibitors (PPIs) are the most effective first‑line therapy for uncomplicated GERD, providing superior symptom relief and esophagitis healing compared with H₂‑receptor antagonists and placebo. (Evidence grade not specified) 77
• Begin treatment with omeprazole 20 mg (or equivalent dose of another PPI) taken 30–60 minutes before breakfast for an initial 4–8‑week trial. (Evidence grade not specified) 77
• Empiric PPI therapy is appropriate for patients presenting with typical heartburn or regurgitation who lack alarm features (e.g., dysphagia, weight loss, anemia, gastrointestinal bleeding); endoscopy is not required initially. (Evidence grade not specified) 77
• If symptoms persist after 4 weeks of standard once‑daily dosing, escalation to twice‑daily PPI dosing (one dose before breakfast, one before dinner) for an additional 4–8 weeks is recommended. (Evidence grade not specified) 77
• Adding a nocturnal H₂‑receptor antagonist to twice‑daily PPI therapy is not recommended because it does not improve efficacy and tachyphylaxis develops within ~6 weeks. (Evidence grade not specified) 77

Essential Lifestyle Modifications

• Weight loss is the single most effective lifestyle intervention (Grade B recommendation) for overweight or obese patients (BMI ≥ 25 kg/m²), improving esophageal pH profiles and GERD symptoms. 77
• Elevating the head of the bed by 6–8 inches in patients with nighttime heartburn or regurgitation improves nocturnal esophageal acid exposure. (Evidence grade not specified) 77
• Avoid lying down for 2–3 hours after meals to reduce esophageal acid exposure. (Evidence grade not specified) 77
• Identify and avoid individual trigger foods based on a detailed dietary history rather than imposing broad dietary restrictions; target only foods that consistently provoke symptoms in each patient. (Evidence grade not specified) 77

Indications for Endoscopic Evaluation

• When symptoms remain uncontrolled after 8–12 weeks of optimized twice‑daily PPI therapy, upper endoscopy should be performed to assess for erosive esophagitis (Los Angeles grade B or higher), Barrett’s esophagus, strictures, eosinophilic esophagitis, or alternative diagnoses. (Evidence grade not specified) 77
• Patients who do not achieve adequate symptom control with twice‑daily PPI therapy are considered treatment failures, marking the upper limit for empirical therapy before proceeding to diagnostic testing. (Evidence grade not specified) 77

Therapies to Avoid

• Metoclopramide should not be used as monotherapy or adjunctive therapy for GERD (Grade D recommendation) because its risk–benefit profile is unfavorable, including the potential for tardive dyskinesia and other extrapyramidal side effects. 77

Management of Extra‑esophageal GERD Manifestations

• For patients presenting with extra‑esophageal symptoms (e.g., chronic cough, laryngitis, globus sensation, asthma) without typical heartburn, initiate twice‑daily PPI dosing from the outset and continue for a minimum of 8–12 weeks before assessing response; these manifestations have lower response rates than typical GERD. (Evidence grade not specified) 78

Evidence‑Based Management of Nocturnal GERD with Extra‑esophageal Symptoms

Pharmacologic Therapy

• Initial therapy: prescribe a once‑daily proton‑pump inhibitor (omeprazole 20 mg or lansoprazole 30 mg) taken 30–60 minutes before breakfast for a 4–8 week trial; this regimen is the most effective first‑line treatment for GERD and is superior to H₂‑receptor antagonists or antacids. 79
• Escalation strategy: if symptoms persist after ≥4 weeks of standard once‑daily dosing, increase to twice‑daily PPI (one dose before breakfast, one before dinner) for an additional 4–8 weeks; this approach improves control of nocturnal and laryngeal manifestations. 80
• Combination therapy: do not add a bedtime H₂‑receptor antagonist to a twice‑daily PPI regimen, as studies show no additional efficacy and tachyphylaxis develops within ~6 weeks; current guidelines explicitly advise against this combination. 79
• Safety reassurance: emphasize that, in patients with confirmed GERD, the therapeutic benefits of PPIs outweigh the potential long‑term risks (e.g., infections, fractures, micronutrient deficiencies). 80

Lifestyle Interventions

• Weight reduction: advise weight loss as the single most effective lifestyle measure for GERD (Grade B evidence); a BMI decrease of ≥3.5 units roughly doubles the likelihood of symptom resolution. 79
• Head‑of‑bed elevation: raise the head of the bed 6–8 inches using sturdy blocks or a wedge (not merely pillows) to decrease nocturnal esophageal acid exposure and enhance acid clearance. 80
• Post‑prandial positioning: instruct patients to remain upright and avoid lying down for 2–3 hours after meals, thereby reducing reflux episodes. 80
• Dietary trigger identification: conduct a detailed dietary history to pinpoint individual reflux‑triggering foods rather than imposing broad restrictions; this personalized approach improves adherence. 79
• Fat intake limitation: recommend limiting dietary fat to ≤45 g per day, because high‑fat meals delay gastric emptying and increase reflux events. 81

Assessment, Monitoring, and Follow‑up

• Early reassessment: evaluate symptom control after the initial 4–8 week PPI trial; for extra‑esophageal symptoms (e.g., laryngeal tightness) allow up to 8–12 weeks before declaring treatment failure. 79
• Endoscopic evaluation: if symptoms remain uncontrolled after 8–12 weeks of optimized twice‑daily PPI plus lifestyle measures, perform upper endoscopy to detect erosive esophagitis, Barrett’s esophagus, strictures, or alternative pathology. 80
• pH monitoring: when endoscopy is normal yet symptoms persist, obtain a 96‑hour wireless esophageal pH study off PPI (withhold therapy 2–4 weeks) to confirm GERD diagnosis and phenotype. 80
• PPI de‑escalation: once symptom relief is achieved, taper the PPI to the lowest effective dose that maintains control; consider on‑demand therapy only in patients without endoscopically proven erosive disease. 79
• Long‑term verification: if PPI therapy extends beyond 12 months without objective confirmation of GERD, schedule endoscopy with prolonged pH monitoring to justify continued long‑term acid suppression. 80

Therapies to Avoid

• Metoclopramide: avoid using metoclopramide as monotherapy or adjunctive therapy for GERD because its risk profile (tardive dyskinesia, extrapyramidal effects) outweighs any modest benefit. 81
• Indefinite empiric PPI: do not continue empiric PPI therapy indefinitely without objective testing if symptoms persist beyond 3 months of optimized treatment. 79

Patient‑Focused Education (Key Points)

• Mechanism of laryngeal symptoms: laryngeal tightness and breathing difficulty stem from acid irritation of the larynx/pharynx rather than primary respiratory disease and typically improve with adequate acid suppression. 81
• Optimal PPI timing: advise taking the PPI 30–60 minutes before breakfast (and before dinner if on twice‑daily dosing) to maximize drug activation when proton pumps are most active. 79
• Symptom timeline: inform patients that while heartburn may improve within days, extra‑esophageal manifestations often require 8–12 weeks of consistent therapy for full resolution. 81
• Cardiac mimicry reassurance: a normal chest radiograph and electrocardiogram are reassuring; however, GERD can produce chest discomfort that mimics cardiac pain, so new or worsening chest pain warrants prompt evaluation. 80
• Use of antacids: antacids may be employed for breakthrough symptoms while on PPI therapy, but they do not prevent reflux episodes; alginate‑containing formulations (e.g., Gaviscon) can provide a protective “raft” for occasional breakthrough. 81

Pharmacologic Management of Reflux Gastritis and Esophagitis

First‑Line Pharmacologic Therapy

• Proton pump inhibitors (PPIs) are the most effective first‑line agents for endoscopically confirmed esophagitis associated with reflux gastritis. 82
• Administer pantoprazole 40 mg or omeprazole 20 mg once daily, 30–60 minutes before breakfast, for 4–8 weeks. 82, 83

Escalation of Therapy When Symptoms Persist

• If symptoms remain after 4 weeks of standard once‑daily dosing, increase the PPI to twice daily (before breakfast and dinner) for an additional 4–8 weeks. 82, 83
• Adding a nighttime H₂‑receptor antagonist to twice‑daily PPI therapy does not improve acid control and leads to tachyphylaxis within 6 weeks. 84

Lifestyle Modifications

• In patients with overweight or obesity (BMI ≥ 25 kg/m²), weight loss is the most effective lifestyle intervention for reducing GERD symptoms (Grade B recommendation). 84, 82
• Raising the head of the bed by 15–20 cm (6–8 inches) decreases nocturnal esophageal acid exposure. 82
• Remain upright for 2–3 hours after meals to lessen reflux episodes. 82
• Identify and avoid individual trigger foods (e.g., coffee, chocolate, alcohol, fatty foods). 82

Diagnostic Evaluation After Optimized Medical Therapy

• After 8–12 weeks of twice‑daily PPI therapy, persistent symptoms warrant upper endoscopy to assess for erosive esophagitis (Los Angeles grade B or higher), Barrett’s esophagus, strictures, or alternative diagnoses. 82, 83
• If endoscopy is normal but symptoms continue, perform a 96‑hour wireless pH monitoring study after a 2–4‑week PPI washout. 82, 83

Long‑Term Management

• Once symptoms are controlled, taper the PPI to the lowest dose that maintains symptom relief. 82, 83
• If PPI therapy exceeds 12 months without objective evidence of GERD, reassess the need for continued treatment with repeat endoscopy and extended pH monitoring. 82, 83

Contraindicated or Discouraged Therapies

• Metoclopramide should not be used as monotherapy or adjunctive therapy for GERD (Grade D recommendation) because the risk of tardive dyskinesia and extrapyramidal side effects outweighs any benefit. 84

Special Clinical Scenarios

• Patients presenting with extra‑esophageal manifestations (chronic cough, laryngitis, globus sensation) should receive twice‑daily PPI therapy from the outset and continue for at least 8–12 weeks before evaluating response. 83

Indications for Antireflux Surgery

• Antireflux surgery is indicated only when all of the following criteria are satisfied: